Background: Adiponectin (APN), which was secreted from adipose tissue, was extensively
investigated in various diseases such as obesity as well as obesity-related cancers.
Method: Here, we investigated serum adiponectin level in gastric cancer (GC) patients and healthy
control subjects using a well-established N-succinimidyl 4-(maleimidomethyl) cyclohexanecarboxylate
(SMCC) modified protein biochip.
Results: We found that serum adiponectin level significantly decreased in the patients with GC when
compared with the controls (p<0.01). Women had higher adiponectin level than men in the controls
(p=0.024), but no gender difference occurred in the GC patients (p>0.05). Correlation analysis between
serum adiponectin expression and clinicopathological characteristics in the GC patients indicated
that serum adiponectin level was obviously correlated with tumor location (p=0.008), differentiated
degree (p=0.011) and histologic type (p=0.006).
Conclusion: Our results revealed that serum adiponectin might potentially reflect location, histogenesis
and differentiation of GC. The biochip immunoassay would act as one substitute of conventional
clinical assays for measuring serum adiponectin in GC.